UNITED
STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C.
20549
___________________
FORM
8-K
___________________
CURRENT
REPORT
Pursuant to
Section 13 or 15(d) of the
Securities Exchange
Act of 1934
Date of Report
(Date of earliest event reported) June 18, 2020
___________________
Cassava Sciences, Inc.
(Exact name of
registrant as specified in its charter)
___________________
|
Delaware
|
|
000-29959
|
|
91-1911336
|
|
(State or other
jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(I.R.S.
Employer
Identification
Number)
|
7801 N Capital of
Texas Highway, Suite 260
Austin, Texas
78731
(Address of
principal executive offices, including zip code)
(512)
501-2444
(Registrant’s
telephone number, including area code)
Not
Applicable
(Former name or
former address, if changed since last report.)
___________________
Check the appropriate box below if
the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following
provisions (see General Instruction A.2 below):
|
|
|
|
☐
|
Written communication pursuant to
Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule
14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communication
pursuant to Rule 14d-2(b) under the Exchange Act (17CFR
240.14d-2(b))
|
|
☐
|
Pre-commencement communication
pursuant to Rule 13e-4(c) under the Exchange Act (17CFR
240.13e-4(c))
|
Securities registered pursuant to
Section 12(b) of the Act:
|
Title of each
class
|
|
Trading
Symbol(s)
|
|
Name of each
exchange on which registered
|
|
Common Stock, $0.001 par
value
|
|
SAVA
|
|
NASDAQ Capital Market
|
Indicate by check mark whether the
registrant is an emerging growth company as defined in as defined
in Rule 405 of the Securities Act of 1933 (§230.405 of this
chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
(§240.12b-2 of this chapter).
Emerging growth
company ☐
If an emerging growth company,
indicate by check mark if the registrant has elected not to use the
extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a)
of the Exchange Act.☐
Item
5.02. Departure
of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.
On June 18, 2020,
Saira Ramasastry notified Cassava Sciences, Inc. (the
“Company”) of her decision to resign as a member of the Board of
Directors of the Company, effective immediately. Ms. Ramasastry
indicated that her decision to resign was due to a potential
conflict of interest and not a result of any disagreement with the
Company on any matter relating to the Company’s operations,
policies or practices.
SIGNATURE
Pursuant to the
requirements of the Securities Exchange Act of 1934, as amended,
the registrant has duly caused this report to be signed on its
behalf by the undersigned thereunto duly authorized.
|
|
|
|
|
|
|
CASSAVA
SCIENCES, INC.
|
|
|
|
a Delaware corporation
|
|
|
|
|
|
|
|
Date:
June 19, 2020
|
|
|
|
|
|
By:
|
/s/
ERIC J.
SCHOEN
|
|
|
|
|
Eric J.
Schoen
|
|
|
|
|
Chief
Financial
Officer
|
|
